Investigational drug · Phase 3
Anlotinib hydrochloride
Also called: AL3818, Catequentenib
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
12 still active
All registered trials
184
Any phase or sponsor naming "Anlotinib hydrochloride"
First trial start
2017
Aug 15, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Anlotinib hydrochloride", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alveolar Soft Part Sarcoma
- Metastatic Colorectal Cancer
- Endometrial Neoplasms
- Ovarian Neoplasms
- Soft Tissue Sarcoma (STS)
- Glioblastoma
- Non-small Cell Lung Caner
- KRAS-mutated
- Metastasis
- Previous Treamted
Approved drugs for the same conditions: Colorectal cancer · Endometrial cancer · Brain tumors (glioma) · Sarcoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Anlotinib hydrochloride" as an intervention, largest first.
- Anlotinib Therapy in Patients With Advanced Lung Cancer.Status unknown
First People's Hospital of HangzhouAcademic, hospital or other
NCT03940404 · 1,000 participants (planned) · Start May 2019 · Primary completion May 2020
Drug: Anlotinib Hydrochloride · For: Lung Neoplasms
Sites: Hangzhou, China
- A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04854668 · 748 participants · Start May 27, 2021 · Primary completion Dec 31, 2024
Drug: Anlotinib hydrochloride capsule; Bevacizumab and 2 more · For: Metastatic Colorectal Cancer
Sites: Chizhou, China; Fuzhou, China; Hefei, China · 92 sites in all
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Pivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04344158 · 648 participants (planned) · Start Aug 11, 2020 · Primary completion Dec 2026
Drug: AK105 Injection; Anlotinib Hydrochloride Capsules and 1 more · For: Advanced Hepatocellular Carcinoma (HCC)
Sites: Bengbu, China; Hefei, China; Beijing, China · 81 sites in all
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07446335 · 578 participants (planned) · Start Apr 2026 · Primary completion Dec 2028
Drug: anlotinib combined with benmelstobart; Toripalimab Combined with Chemotherapy · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Zhengzhou, China
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05718167 · 570 participants (planned) · Start Feb 2023 · Primary completion Oct 2024
Drug: TQB2450; Anlotinib hydrochloride capsule and 1 more · For: Advanced Squamous Non-Small Cell Lung Carcinoma
Sites: Beijing, China; Tianjin, China; Kunming, China · 4 sites in all
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Pivotal-lookingRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07165951 · 566 participants (planned) · Start Dec 2, 2025 · Primary completion May 2028
Drug: TQB2868 Injection; Anlotinib Hydrochloride Capsules and 3 more · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 71 sites in all
- A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04385550 · 528 participants (planned) · Start May 20, 2020 · Primary completion Oct 31, 2023
Drug: Anlotinib hydrochloride capsule; AK105 injection and 2 more · For: Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
Sites: Hefei, China; Beijing, China; Fuzhou, China · 45 sites in all
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04523272 · 528 participants · Start Aug 25, 2020 · Primary completion Jun 2025
Drug: TQB2450; Anlotinib and 1 more · For: Advanced Renal Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 39 sites in all
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.Pivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05862337 · 480 participants (planned) · Start May 10, 2023 · Primary completion Aug 2024
Drug: Anlotinib hydrochloride capsules, Penpulimab injection; Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo · For: Hepatocellular Carcinoma
Sites: Bengbu, China; Hefei, China; Beijing, China · 67 sites in all
- Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed GlioblastomaPivotal-lookingStatus unknown
People's Hospital of Guangxi Zhuang Autonomous RegionAcademic, hospital or other
NCT04157478 · 464 participants (planned) · Start Jan 2020 · Primary completion Dec 2022
Drug: Anlotinib Hydrochloride; Temozolomide · For: Glioblastoma
Sites: Guilin, China; Liuzhou, China; Nanning, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A trimodal combination therapy utilizing cryogel microparticles for hepatocellular carcinoma.
Zhao Y, Liu Y, Shan J, et al. · Colloids Surf B Biointerfaces 2026
- Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review.
Zhao G, Han G, Yang X, et al. · Front Oncol 2026
- Retraction: Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Xu Q, Huang K, Meng X, et al. · Clin Cancer Res 2026
- A study on the efficacy and safety of anlotinib in patients with metastatic pheochromocytoma and paraganglioma.
Cui Y, Zhou Y, Zhang W, et al. · Endocr Relat Cancer 2025
- Etoposide combined with anlotinib and sintilimab successfully achieved long term progression-free survival in platinum-refractory ovarian cancer: A case report.
Zhang L, Wang Y, Qiu C, et al. · Gynecol Oncol Rep 2025
- Efficacy and safety of anlotinib hydrochloride combined with concurrent radiotherapy in the treatment of locally advanced cervical cancer: a single-arm, single-center, exploratory, phase II clinical study.
Liu H, Chang X, Hong Y, et al. · Front Oncol 2025
Also in development for Alveolar Soft Part Sarcoma
- BenmelstobartPhase 24 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Alveolar Soft Part Sarcoma, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.